NCT04333225

Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers

A Prospective Clinical Study of Hydroxychloroquine in the Prevention of SARS- CoV-2 (COVID-19) Infection in Healthcare Workers After High-risk Exposures

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 221 (actual)
• Sponsor: Baylor Research Institute · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

In order to assess the efficacy of hydroxychloroquine treatment weekly for a total of 7 weeks in the prevention of COVID-19 infection, three hundred sixty (360) Healthcare workers with high risk exposure to patients infected with COVID-19 will be tested for COVID-19 infection via nasopharyngeal (NP) swab once weekly for 7 weeks. Of those, one hundred eighty (180) will receive weekly doses of hydroxychloroquine for the duration of the study. Subjects who opt not to receive the study drug will form the control group.

Conditions

• COVID-19

Interventions

Type	Name	Description
DRUG	Hydroxychloroquine	Weekly treatment in individuals at high risk

Timeline

• Start date: 2020-04-03
• Primary completion: 2020-06-30
• Completion: 2020-06-30
• First posted: 2020-04-03
• Last updated: 2021-08-20
• Results posted: 2021-08-20

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study